Akebia Ther (AKBA) - Total Liabilities
Based on the latest financial reports, Akebia Ther (AKBA) has total liabilities worth $343.95 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AKBA net asset momentum to track the company's year-over-year net asset growth rate.
Akebia Ther - Total Liabilities Trend (2012–2025)
This chart illustrates how Akebia Ther's total liabilities have evolved over time, based on quarterly financial data. See Akebia Ther (AKBA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Akebia Ther Competitors by Total Liabilities
The table below lists competitors of Akebia Ther ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
USA | $5.84 Million |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
Israel | ILA1.01 Billion |
|
Gladstone Land Corporation
NASDAQ:LAND
|
USA | $568.89 Million |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
China | CN¥276.73 Million |
|
Super Group Ltd.
JSE:SPG
|
South Africa | ZAC25.13 Billion |
|
Trifork Holding AG
CO:TRIFOR
|
Denmark | Dkr164.52 Million |
|
Pollard Banknote Limited
TO:PBL
|
Canada | CA$315.29 Million |
|
Beijing LabTech Instruments Co Ltd
SHG:688056
|
China | CN¥113.93 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Akebia Ther's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Akebia Ther worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akebia Ther's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akebia Ther (2012–2025)
The table below shows the annual total liabilities of Akebia Ther from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $343.95 Million | +27.46% |
| 2024-12-31 | $269.86 Million | -0.89% |
| 2023-12-31 | $272.29 Million | -22.39% |
| 2022-12-31 | $350.82 Million | -22.95% |
| 2021-12-31 | $455.34 Million | +14.83% |
| 2020-12-31 | $396.52 Million | +5.33% |
| 2019-12-31 | $376.44 Million | +4.39% |
| 2018-12-31 | $360.61 Million | +47.24% |
| 2017-12-31 | $244.92 Million | +5.52% |
| 2016-12-31 | $232.10 Million | +1843.53% |
| 2015-12-31 | $11.94 Million | +72.65% |
| 2014-12-31 | $6.92 Million | +76.91% |
| 2013-12-31 | $3.91 Million | -20.59% |
| 2012-12-31 | $4.92 Million | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more